Immune evasion after SARS-CoV-2 Omicron BA.5 and XBB.1.9 endemic observed from Guangdong Province, China from 2022 to 2023.

IF 4 3区 医学 Q2 VIROLOGY Virology Journal Pub Date : 2024-11-20 DOI:10.1186/s12985-024-02573-x
Huan Zhang, Baisheng Li, Jiufeng Sun, Lirong Zou, Lina Yi, Huifang Lin, Pingping Zhou, Chumin Liang, Lilian Zeng, Xue Zhuang, Zhe Liu, Jing Lu, Jianfeng He, Runyu Yuan
{"title":"Immune evasion after SARS-CoV-2 Omicron BA.5 and XBB.1.9 endemic observed from Guangdong Province, China from 2022 to 2023.","authors":"Huan Zhang, Baisheng Li, Jiufeng Sun, Lirong Zou, Lina Yi, Huifang Lin, Pingping Zhou, Chumin Liang, Lilian Zeng, Xue Zhuang, Zhe Liu, Jing Lu, Jianfeng He, Runyu Yuan","doi":"10.1186/s12985-024-02573-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>From 2022 to 2023, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused by Omicron variants spread rapidly in Guangdong Province, resulting in over 80% of the population being infected.</p><p><strong>Results: </strong>To investigate the levels of neutralizing antibodies (NAbs) in individuals following the rapid pandemic and to evaluate the cross-protection against currently circulating variants of SARS-CoV-2 in China, neutralization assay and magnetic particle chemiluminescence method were used to test the 117 serum samples from individuals who had recovered 4 weeks post-infection. The results indicated that the levels of NAbs against prototype and Omicron variants BA.5 were significantly higher than those against Omicron variants BQ.1, XBB.1.1, XBB.1.9, XBB.1.16 and EG.5, regardless of whether the infection was primary or secondary.</p><p><strong>Conclusions: </strong>The cross-protection provided by NAbs induced by prototype and Omicron BA.5 variants was limited when challenged by BQ.1, XBB.1.1, XBB.1.9, XBB.1.16 and EG.5 variants. This indicates that we should pay more attention to the risk of multiple infection from any novel Omicron variants that may emerge in the near future.</p>","PeriodicalId":23616,"journal":{"name":"Virology Journal","volume":"21 1","pages":"298"},"PeriodicalIF":4.0000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12985-024-02573-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: From 2022 to 2023, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused by Omicron variants spread rapidly in Guangdong Province, resulting in over 80% of the population being infected.

Results: To investigate the levels of neutralizing antibodies (NAbs) in individuals following the rapid pandemic and to evaluate the cross-protection against currently circulating variants of SARS-CoV-2 in China, neutralization assay and magnetic particle chemiluminescence method were used to test the 117 serum samples from individuals who had recovered 4 weeks post-infection. The results indicated that the levels of NAbs against prototype and Omicron variants BA.5 were significantly higher than those against Omicron variants BQ.1, XBB.1.1, XBB.1.9, XBB.1.16 and EG.5, regardless of whether the infection was primary or secondary.

Conclusions: The cross-protection provided by NAbs induced by prototype and Omicron BA.5 variants was limited when challenged by BQ.1, XBB.1.1, XBB.1.9, XBB.1.16 and EG.5 variants. This indicates that we should pay more attention to the risk of multiple infection from any novel Omicron variants that may emerge in the near future.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2022 年至 2023 年在中国广东省观察到的 SARS-CoV-2 Omicron BA.5 和 XBB.1.9 流行后的免疫逃避。
背景:2022年至2023年,由Omicron变种引起的严重急性呼吸系统综合征冠状病毒2型(SARS-CoV-2)在广东省迅速传播,导致80%以上的人口受到感染:为了研究快速大流行后个人体内的中和抗体(NAbs)水平,并评估对目前在中国流行的 SARS-CoV-2 变体的交叉保护作用,我们使用中和测定法和磁粉化学发光法检测了 117 份感染后 4 周康复者的血清样本。结果表明,无论原发性感染还是继发性感染,针对原型和Omicron变种BA.5的NAbs水平均明显高于针对Omicron变种BQ.1、XBB.1.1、XBB.1.9、XBB.1.16和EG.5的NAbs水平:结论:当受到BQ.1、XBB.1.1、XBB.1.9、XBB.1.16和EG.5变体的挑战时,原型和Omicron BA.5变体诱导的NAbs所提供的交叉保护是有限的。这表明,我们应该更加关注不久的将来可能出现的任何新型 Omicron 变体造成多重感染的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Virology Journal
Virology Journal 医学-病毒学
CiteScore
7.40
自引率
2.10%
发文量
186
审稿时长
1 months
期刊介绍: Virology Journal is an open access, peer reviewed journal that considers articles on all aspects of virology, including research on the viruses of animals, plants and microbes. The journal welcomes basic research as well as pre-clinical and clinical studies of novel diagnostic tools, vaccines and anti-viral therapies. The Editorial policy of Virology Journal is to publish all research which is assessed by peer reviewers to be a coherent and sound addition to the scientific literature, and puts less emphasis on interest levels or perceived impact.
期刊最新文献
Immune evasion after SARS-CoV-2 Omicron BA.5 and XBB.1.9 endemic observed from Guangdong Province, China from 2022 to 2023. SARS-CoV-2 surveillance in captive animals at the belo horizonte zoo, Minas Gerais, Brazil. EMCV VP2 degrades IFI16 through Caspase-dependent apoptosis to evade IFI16-STING pathway. A humanized neutralizing antibody protects against human adenovirus type 7 infection in humanized desmoglein-2 and CD46 double-receptor transgenic mice. Altered colonic microflora and its metabolic profile in mice with acute viral myocarditis induced by coxsackievirus B3.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1